The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

Background: The risk of infection including tuberculosis (TB) infection or reactivation during biological therapy with the current various clinical application is a major concern. This risk may be higher in countries endemic to TB. Our aim of this study is to determine the risk of TB infection in pa...

詳細記述

書誌詳細

出版年:	Journal of Infection and Public Health
主要な著者:	Abdulaziz Boqaeid, Laila Layqah, Amgad Alonazy, Mutaz Althobaiti, Al-zahraa Almahlawi, Abdullah Al-Roqy, Omar Baharoon, Abdullah Alsaeedi, Jinan Shamou, Salim Baharoon
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2024-06-01
主題:	Adalimumab Etanercept Tocilizumab Rheumatoid arthritis Tuberculosis infection
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1876034124001291